GSK plc - Company Profile
Powered by
All the data and insights you need on GSK plc in one report.
- Save hours of research time and resources with
our up-to-date GSK plc Strategy Report
- Understand GSK plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreBusiness Description
GSK plc (GSK) is focused on research, development and manufacturing of novel pharmaceutical medicines, vaccines and consumer healthcare products. The company classifies its business into two reportable segments: Commercial operations and Total R&D.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
GSK’s R&D activities are focused on developing new and improved vaccines, prophylactic and therapeutic vaccines related to several therapeutic areas including respiratory, cancer, HIV, immuno-inflammation, infectious diseases and other diseases. In FY2023, the company spent GBP5,750 million on R&D. It has major research centers in the UK, the US, Canada, Asia (Singapore and China) and Europe (Spain, Belgium and Germany). GSK has partnerships (pharmaceuticals) with academic institutions, public-private partnerships, pharmaceutical companies and biotechnology companies; and external scientific partnerships (vaccines) with scientists and leading academic and public health institutions. GSK owns numerous domestic and foreign patents cover pharmaceutical and vaccine products and their uses, product manufacturing processes and pharmaceutical formulations. As of FY2023, the company’s pipeline consisted of 71 vaccines and medicines under development. The company developed products in the field of infectious diseases, HIV, immunology/respiratory and oncology. It’s major product developments are Bepirovirsen for Chronic hepatitis B in the field of infectious diseases; Nucala (mepolizumab) for COPD; and Jemperli, Zejula and Blenrep for the treatment of different kind of cancers in the field of oncology.
Business Segments
Overview
Discovers, develops and commercializes drugs to treat a wide range of diseases and therapy areas. The Pharmaceuticals segment derives revenue from three product categories, namely, Specialty Medicines, Vaccines and General Medicines. - Marketed products for HIV, oncology, immuno-inflammation, respiratory and other specialty medicines (including Nucala) and the COVID-19 solution, Xevudy in Speciality Medicines category. - Products marketed under Vaccines include GSK’s AS03 adjuvant. - Major products marketed as General Medicines are Trelegy, Ellipta and Anoro Ellipta.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes research and development endeavors spanning specialty medicines, which includes areas such as HIV and Vaccines.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer